Tokyo Tape
Sign in
← PHC Holdings

Half-year report · Q2

6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥353.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥13.2bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥12.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥525.4bnat 2024-09-30Cons.Assets IFRS
Total assets¥564.3bnat 2024-03-31Cons.Assets IFRS
Total assets¥570.4bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥398.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥425.2bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥139.5bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-102.482023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-102.482023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥951m
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 812
ItemContextValueUnit
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration11000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration-1523000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration62215000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration－JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-75514000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-13518000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-2877000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-3631000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1YTDDuration171000000JPY
Proceeds from issuance of shares fin cf IFRSCurrentYTDDuration37000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration-2611000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration－JPY
Dividends paid to owners of parent fin cf IFRSPrior1YTDDuration-4512000000JPY
Dividends paid to owners of parent fin cf IFRSCurrentYTDDuration-2268000000JPY
Other fin cf IFRSPrior1YTDDuration-496000000JPY
Other fin cf IFRSCurrentYTDDuration-14000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-23613000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-20920000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration3565000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration-1937000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration504000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-14074000000JPY
Cash and cash equivalents IFRSPrior2YearInstant60933000000JPY
Cash and cash equivalents IFRSPrior1YearInstant47044000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant61437000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant32969000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember48769000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember55910000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember61015000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember165695000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember1123000000JPY
Revenue from external customers IFRSPrior1YTDDuration166819000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember48769000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember55910000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember61015000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember165695000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember1123000000JPY
Revenue IFRSPrior1YTDDuration166819000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember5539000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember951000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2453000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember8944000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-4761000000JPY
Operating profit loss IFRSPrior1YTDDuration4182000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass